Literature DB >> 14551145

Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events.

Gavin Babbage1, Richard Garand, Nelly Robillard, Niklas Zojer, Freda K Stevenson, Surinder S Sahota.   

Abstract

Isotype switch commonly follows onset of somatic hypermutation in the germinal center (GC), with activation-induced cytidine deaminase (AID) as a prerequisite. Mantle cell lymphoma (MCL) with t(11;14) includes a subset with unmutated (UM) and a minor subset with mutated (MUT) VH genes. Here, we investigated whether switch events and AID expression occur in MCL. In 4 of 6 UM and 4 of 7 MUT MCLs, alternative tumor-derived Cgamma,alpha,epsilon transcripts were identified. AID transcripts, including a splice variant, were common to both subsets. AID expression correlated with switch in 8 of 8 cases, but in 3 of 5 cases it occurred with switch absent. Circle transcripts (Igamma-Cmicro/Ialpha-Cmu) were identified in 5 of 7 evaluated cases. In 1 of 12 cases, 12% of tumor cells expressed immunoglobulin L-restricted surface IgA. Ongoing switch recombination events appear to be a feature of MCL, likely restricted to a minor tumor subpopulation, with occasional variant sIg expression. UM MCLs implicate origins from pre-GC B cells and reveal switch events at ectopic sites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551145     DOI: 10.1182/blood-2003-05-1632

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.

Authors:  Jin-Qing Liu; Pramod S Joshi; Chuansong Wang; Hani Y El-Omrani; Yi Xiao; Xiuping Liu; John P Hagan; Chang-Gong Liu; Lai-Chu Wu; Xue-Feng Bai
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

2.  A novel human B cell subpopulation representing the initial germinal center population to express AID.

Authors:  Grant R Kolar; Darshna Mehta; Rosana Pelayo; J Donald Capra
Journal:  Blood       Date:  2006-11-28       Impact factor: 22.113

Review 3.  Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis.

Authors:  Sarah H Walsh; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells.

Authors:  Xiaosheng Wu; Jaime R Darce; Sook Kyung Chang; Grzegorz S Nowakowski; Diane F Jelinek
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

Review 5.  Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.

Authors:  Sylvia Hoeller; Yi Zhou; Rashmi Kanagal-Shamanna; Zijun Y Xu-Monette; Daniela Hoehn; Michel Bihl; Steven H Swerdlow; Andreas Rosenwald; German Ott; Jonathan Said; Cherie H Dunphy; Carlos E Bueso-Ramos; Pei Lin; Michael Wang; Roberto N Miranda; Alexander Tzankov; L Jeffrey Medeiros; Ken H Young
Journal:  Hum Pathol       Date:  2012-08-31       Impact factor: 3.466

6.  Splice variants of activation induced deaminase (AID) do not affect the efficiency of class switch recombination in murine CH12F3 cells.

Authors:  Cesare Sala; Giorgio Mattiuz; Silvia Pietrobono; Andrea Chicca; Silvestro G Conticello
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 7.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

8.  Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4.

Authors:  Simone Valentin Hansen; Marcus Høy Hansen; Oriane Cédile; Michael Boe Møller; Jacob Haaber; Niels Abildgaard; Charlotte Guldborg Nyvold
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.